John Paulson, Director at Valeant Pharmaceuticals International, Inc. (VRX), bought 344,216 shares at $14.40 ($5.0M) on 2017-11-16, disclosed to the SEC on 2017-11-20.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| BHC | BUY | 2025-06-17 | $42.3M | — | Filing → |
| BHC | BUY | 2025-06-12 | $29.4M | — | Filing → |
| BSIG | BUY | 2020-06-26 | $12.7M | — | Filing → |